Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM2RJ4D)

• Drug Name: MM-141 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Pancreatic cancer	2C10	Phase 2	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 2	[2]

• Cross-matching ID: TTD Drug ID: DM2RJ4D

Molecule-Related Drug Atlas

Drug(s) Targeting Insulin-like growth factor I receptor (IGF1R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Teprotumumab	DM4L59B	Graves disease	5A02.0	Approved	[4]
Mecasermin	DM1O3BY	Growth failure	LD2F.1Y	Approved	[5]
Somatomedin-1	DMZ9FAO	Hormone deficiency	5A61.1	Approved	[6]
OSI-906	DMHKZLF	Solid tumour/cancer	2A00-2F9Z	Phase 3	[7]
Rinfabate	DML9FD4	Solid tumour/cancer	2A00-2F9Z	Phase 2/3	[8]
TT-100	DMZE6Y9	Non-small-cell lung cancer	2C25.Y	Phase 2	[9]
AMG 479	DM0DRAZ	Breast cancer	2C60-2C65	Phase 2	[10]
VPI-2690B	DMUQZT4	Diabetic nephropathy	GB61.Z	Phase 2	[11]
AXL-1717	DMTQ1Y3	Solid tumour/cancer	2A00-2F9Z	Phase 2	[12]
R1507	DMIUS5X	Graves ophthalmopathy	9C82.3	Phase 2	[13]

Drug(s) Targeting Serine/threonine-protein kinase mTOR (mTOR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sirolimus	DMGW1ID	Multiple myeloma	2A83	Approved	[14]
Temsirolimus	DMS104F	Renal cell carcinoma	2C90	Approved	[15]
PF-04449913	DMSB068	Chronic myelomonocytic leukaemia	2A40	Approved	[16]
Everolimus	DM8X2EH	Renal cell carcinoma	2C90	Approved	[17]
Novolimus	DM6ZPLQ	Artery stenosis	BD52	Approved	[18]
Zotarolimus	DMRMCXW	Solid tumour/cancer	2A00-2F9Z	Approved	[19]
Ridaforolimus	DMLHEU7	Sarcoma	2A60-2C35	Phase 3	[20]
Azd2014	DMOEARH	Solid tumour/cancer	2A00-2F9Z	Phase 2	[21]
PQR309	DMMCYZ8	Squamous head and neck cell carcinom	2D60.0	Phase 2	[18]
Salirasib	DMRSU4X	Lung cancer	2C25.0	Phase 2	[18]

Drug(s) Targeting Erbb3 tyrosine kinase receptor (Erbb-3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MEHD-7945A	DMHOF7T	Colorectal cancer	2B91.Z	Phase 2	[22]
Seribantumab	DMYT470	Colorectal cancer	2B91.Z	Phase 2	[23]
CDX-3379	DM5GKYD	Squamous cell carcinoma	2B60-2D01	Phase 2	[23]
MM-121	DMDJRU1	Breast cancer	2C60-2C65	Phase 2	[24]
Elisidepsin	DMB38KH	Psoriasis vulgaris	EA90	Phase 2	[25]
Sym013	DMZM6I2	Epithelial ovarian cancer	2B5D	Phase 1/2	[1]
Zenocutuzomab	DMMQGPE	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[26]
LJM716	DMGTB5N	Breast cancer	2C60-2C65	Phase 1/2	[27]
AMG888/U3-1287	DMEF4L5	Non-small-cell lung cancer	2C25.Y	Phase 1/2	[28]
MM-151	DMXQHZC	Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Erbb3 tyrosine kinase receptor (Erbb-3)	TTDC8N2	ERBB3_HUMAN	Modulator	[3]
Insulin-like growth factor I receptor (IGF1R)	TTHRID2	IGF1R_HUMAN	Modulator	[3]
Serine/threonine-protein kinase mTOR (mTOR)	TTCJG29	MTOR_HUMAN	Inhibitor	[1]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] ClinicalTrials.gov (NCT02399137) A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer. U.S. National Institutes of Health.
• [3] MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Mol Cancer Ther. 2014 Feb;13(2):410-25.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [5] IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer. Virchows Arch. 2003 Aug;443(2):139-45.
• [6] 2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006).
• [7] Imidazo[2,1-b]thiazoles: multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family... Bioorg Med Chem Lett. 2010 Apr 15;20(8):2452-5.
• [8] Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3. Drugs R D. 2005;6(2):120-7.
• [9] BiPar Sciences Co-founder Reunites Management Team At TriAct Therapeutics to Advance Clinical Stage Cancer Programs. TriAct Therapeutics. Sept. 10, 2009.
• [10] Clinical pipeline report, company report or official report of Amgen (2009).
• [11] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [12] Clinical Phase I study with an Insulin-like Growth Factor-1 receptor inhibitor: experiences in patients with squamous non-small cell lung carcinoma. Acta Oncol. 2011 Apr;50(3):441-7.
• [13] Clinical pipeline report, company report or official report of Roche (2009).
• [14] Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
• [15] Advances in kinase targeting: current clinical use and clinical trials. Trends Pharmacol Sci. 2014 Nov;35(11):604-20.
• [16] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [17] Mammalian target of rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma. Gan To Kagaku Ryoho. 2009 Jul;36(7):1076-9.
• [18] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
• [19] Natural products to drugs: natural product-derived compounds in clinical trials. Nat Prod Rep. 2008 Jun;25(3):475-516.
• [20] A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
• [21] Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014. Biochem Biophys Res Commun. 2014 Jan 10;443(2):406-12.
• [22] Company report (Biooncology)
• [23] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [24] Company report (Merrimack)
• [25] Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models. Eur J Cancer. 2009 Jul;45(10):1855-64.
• [26] Clinical pipeline report, company report or official report of Merus.
• [27] An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin. Cancer Res. 2013 Oct 1;73(19):6024-35.
• [28] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1798).